Sun Pharmaceutical, its Founder Dilip Shanghvi, and nine others have settled a probe with markets regulator SEBI for violating insider trading norms by paying â‚¹18 lakh settlement charges. The case is reportedly in relation to Sun Pharma's acquisition of Ranbaxy from Japanese drug maker Daiichi. However, SEBI agreed to settle the case after the entities approached it with settlement plea.